Evidence map›Paper›PMID 32155191›Full record

ArticlePloS one2020

Brain Shuttle Neprilysin reduces central Amyloid-β levels.

Christopher R Campos, Alicia M Kemble, Jens Niewoehner, Per-Ola Freskgård, Eduard Urich

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Antibody-Based Biologics for CNS Disorders.Antibodies (Basel, Switzerland) · 2026
    Review
  3. Review
  4. Bispecific brain-penetrant antibodies for treatment of Alzheimer's disease.The journal of prevention of Alzheimer's disease · 2025
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Christopher R CamposNeuroscience Discovery, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Alicia M KembleNeuroscience Discovery, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Jens NiewoehnerLarge Molecule Research, Roche Pharma Research and Early Development, Roche Innovation Center Munich, Munich, Germany.
Per-Ola FreskgårdNeuroscience Discovery, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Eduard UrichNeuroscience Discovery, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.ORCID 0000-0003-0238-5517
Roche (Switzerland) · CHRoche Pharma AG (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reducing Amyloid β (Aβ) in the brain is of fundamental importance for advancing the therapeutics for Alzheimer`s disease. The endogenous metallopeptidase neprilysin (NEP) has been identified as one of the key Aβ-degrading enzymes. Delivery of NEP to the brain by utilizing the Brain Shuttle (BS) transport system offers a promising approach for clearing central Aβ. We fused the extracellular catalytic domain of NEP to an active or inactive BS module. The two BS-NEP constructs were used to investigate the pharmacokinetic/pharmacodynamics relationships in the blood and the cerebrospinal fluid (CSF) in dose-response and multiple dosing. As previously shown, NEP was highly effective at degrading Aβ in blood but not in the CSF compartment after systemic administration. In contrast, the NEP with an active BS module led to a significant CSF exposure of BS-NEP, followed by substantial Aβ reduction in CSF and brain parenchyma. Our data show that a BS module against the transferrin receptor facilitates the transport of an Aβ degrading enzyme across the blood-brain barriers to efficiently reduce Aβ levels in both CSF and brain.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAnimalsBlood-Brain BarrierBrainHEK293 CellsHumansNeprilysinRatsRats, WistarRecombinant Fusion ProteinsAmyloid beta-PeptidesNeprilysinRecombinant Fusion Proteins

Identifiers

PMID32155191
PMCPMC7064168
OpenAlexW3012015620

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.